Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INCYTE CORPORATION

(INCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société INCYTE CORPORATION
05/17INCYTE  : Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxo..
BU
05/12INCYTE  : Data From Incyte's Oncology Portfolio Accepted for Presentation at the..
BU
05/04INCYTE  : Management's Discussion and Analysis of Financial Condition and Result..
AQ
05/04INCYTE : Q1 Earnings Snapshot
AQ
05/04INCYTE CORP  : Results of Operations and Financial Condition, Financial Statemen..
AQ
05/04INCYTE  : Reports 2021 First Quarter Financial Results and Provides Updates on K..
BU
05/03INCYTE  : Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for ..
BU
04/27INCYTE  : to Present at Upcoming Investor Conference
BU
04/26ELI LILLY AND  : OLUMIANT Showed Significant Improvements in the Severity and Ex..
AQ
04/23INCYTE  : Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib ..
BU
04/23INCYTE  : Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Pro..
BU
04/20MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Eva..
AQ
04/20INCYTE  : Multiple Abstracts from Incyte's Dermatology Portfolio Accepted for Pr..
BU
04/13INCYTE  : to Report First Quarter Financial Results
BU
04/06INCYTE  : Lilly and Incyte communicate review extension of supplemental New Drug..
PR
03/31BRIACELL THERAPEUTICS  : to Present at the American Association for Cancer Resea..
AQ
03/30INCYTE  : Pemazyre® approved for adult patients with cholangiocarcinoma in Europ..
AQ
03/29INCYTE  : Announces the European Commission Approval of Pemazyre® (pemigatinib) ..
BU
03/23INCYTE  : Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatme..
BU
03/18INCYTE  : Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib..
BU
03/11INCYTE  : Announces Data from Multiple Programs Within its Oncology Portfolio Ac..
BU
03/04ELI LILLY AND COMPANY  : - Baricitinib is First JAK-Inhibitor to Demonstrate Hai..
AQ
02/26INCYTE  : Announces the Validation by the European Medicines Agency of its Marke..
BU
02/24INCYTE  : Annual Call for Submissions Open for the Incyte Ingenuity Award Progra..
PU
02/22INCYTE  : Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxoliti..
BU
02/19INCYTE  : Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream ..
BU
02/19INCYTE CORP  : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, ..
AQ
02/11INCYTE  : to Present at Upcoming Investor Conference
BU
02/09INCYTE  : Management's Discussion and Analysis of Financial Condition and Result..
AQ
02/09INCYTE : 4Q Earnings Snapshot
AQ
02/09INCYTE CORP  : Results of Operations and Financial Condition, Financial Statemen..
AQ
02/09INCYTE  : Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2..
BU
01/29INCYTE  : Announces Positive CHMP Opinion for Pemigatinib for the Treatment of A..
BU
01/21INCYTE  : Announces Acceptance and Priority Review of BLA for Retifanlimab as a ..
BU
01/19INCYTE  : to Report Fourth Quarter and Year-End 2020 Financial Results
BU
01/13BRIACELL THERAPEUTICS  : Announces Presentation at the 2021 Keystone Symposia Co..
AQ
01/12INCYTE  : and MorphoSys Announce Acceptance by Health Canada of the New Drug Sub..
AQ
01/06INCYTE  : MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketi..
AQ
2020INCYTE  : and Cellenkos Enter into Global Development Collaboration Agreement fo..
BU
2020ELI LILLY AND COMPANY  : - Data from ACTT-2 Trial of Baricitinib in Hospitalized..
AQ
2020INCYTE  : Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) a..
BU
2020BRIACELL THERAPEUTICS  : Presents Clinical Data at the 2020 San Antonio Breast C..
AQ
2020INCYTE  : to Present at Upcoming Investor Conference
BU
2020MorphoSys AG - Data Evaluating Tafasitamab with and without Lenalidomide in C..
AQ
2020INCYTE  : Announces Parsaclisib Treatment Results in High Rate of Rapid and Dura..
BU
2020INCYTE  : Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) S..
BU
2020ELI LILLY AND COMPANY  : - Baricitinib Receives Emergency Use Authorization from..
AQ
2020INCYTE  : Baricitinib Receives Emergency Use Authorization from the FDA for the ..
PR
2020INCYTE  : to Present at Upcoming Investor Conference
BU
2020INCYTE  : Xencor, MorphoSys and Incyte Enter into Global Development Collaborati..
BU
2020INCYTE  : Data from Incyte's Oncology Portfolio Accepted for Presentation at the..
BU
2020Qualcomm, Upwork rise; Hanesbrands, Incyte fall
AQ
2020Qualcomm, Upwork rise; Hanesbrands, Incyte fall
AQ
2020INCYTE  : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2020INCYTE : 3Q Earnings Snapshot
AQ
2020INCYTE CORP  : Results of Operations and Financial Condition, Financial Statemen..
AQ
2020INCYTE  : Reports 2020 Third Quarter Financial Results and Provides Updates on K..
BU
2020INCYTE  : More than 40 Abstracts from Incyte's Oncology Portfolio Accepted for P..
BU
2020ELI LILLY AND COMPANY  : - ACR 2020, Lilly and Incyte Highlight Positive Data fo..
AQ
2020ELI LILLY AND COMPANY  : - Fall Clinical Dermatology 2020, Lilly and Incyte Show..
AQ
2020ELI LILLY AND COMPANY  : - EADV 2020, Lilly and Incyte Showcase New Data for Bar..
AQ
2020INCYTE  : Ranked Second Among Science Magazine's 2020 Top Biopharma Employers
BU
2020INCYTE  : Pooled Results from Incyte's TRuE-AD1 and TRuE-AD2 Atopic Dermatitis S..
BU
2020INCYTE  : Announces Health Canada Acceptance of the New Drug Submission for Pemi..
AQ
2020BRIACELL THERAPEUTICS  : Breast Cancer Survival Data, 13.3 Months versus 7.2-9.8..
AQ
2020INCYTE  : to Report Third Quarter Financial Results
BU
2020ELI LILLY AND COMPANY  : - Baricitinib has Significant Effect on Recovery Time, ..
AQ
2020INCYTE  : Baricitinib has Significant Effect on Recovery Time, Most Impactful in..
PR
2020BRIACELL THERAPEUTICS  : to Present Clinical Findings at the 2020 San Antonio Br..
AQ
2020MACROGENICS  : Announces Development Milestone Achieved in Retifanlimab Collabor..
AQ
2020MorphoSys and Incyte to Host Investor Event to Discuss the Unmet Need and Glo..
AQ
2020INCYTE  : CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of A..
PR
2020INCYTE  : Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCM..
BU
2020INCYTE  : and MorphoSys to Host Investor Event to Discuss the Unmet Need and Glo..
BU
2020INCYTE  : Baricitinib in Combination with Remdesivir Reduces Time to Recovery in..
AQ
1  2  3  4  5  6  7  8  9Next
Official Publications
05/04Press Release 
05/041st quarter results 
05/04SEC Filing 10Q-1 
05/04SEC Filing 8K 
04/23Report 
04/09Report 
Upcoming event on INCYTE CORPORATION
05/26/21